Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Medicine Reports

• Publication date

  2015-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/mmr.2015.4422PMID 26460271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of the Function of the Human ABCG2 Multidrug Transporter by Cholesterol and Bile Acids: Effects of Mutations in Potential Substrate and Steroid Binding Sites

  2014cited by this paper
• VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE‐1 study

  2014cited by this paper
• Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.

  2013cited by this paper
• Biology and clinical implications of CD133(+) liver cancer stem cells.

  2013cited by this paper
• Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures

  2013cited by this paper
• Positive Correlation of Oct4 and ABCG2 to Chemotherapeutic Resistance in CD90+CD133+ Liver Cancer Stem Cells

  2013cited by this paper
• The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression

  2013cited by this paper
• A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches.

  2012cited by this paper
• Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma

  2012cited by this paper
• c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells

  2012cited by this paper
• Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma

  2012cited by this paper
• Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446.

  2012cited by this paper
• Mitogen-activated protein kinases in hepatocellular carcinoma development.

  2011cited by this paper
• Hepatocellular carcinoma.

  2011cited by this paper
• JNK signalling modulates intestinal homeostasis and tumourigenesis in mice

  2009cited by this paper
• FDA approves sorafenib for patients with inoperable liver cancer.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand

  2008cited by this paper
• Sorafenib for the Treatment of Advanced Renal Cell Carcinoma

  2006cited by this paper
• Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

  2006cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Multipotential stem cells and 'side population' cells.

  2002cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper

• A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability

  2023cites this paper
• Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells

  2022cites this paper
• Role of ATP-binding Cassette Transporters in Sorafenib Therapy for Hepatocellular Carcinoma: an overview.

  2021cites this paper
• Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems

  2021cites this paper
• Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R)

  2020cites this paper
• Molecular Bases of Drug Resistance in Hepatocellular Carcinoma

  2020influential citation
• A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis

  2016cites this paper